ReviewEmerging infectious diseases
Emergence of vancomycin-resistant enterococci.
Review in Emerging infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 273 citations in OpenAlex.
- Prevalence of Vancomycin resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures.Antimicrobial agents and chemotherapy · 2003Trial
- Article
- An Overview ofIndian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
- Insights into ecology, pathogenesis, and biofilm formation ofMicrobiology and molecular biology reviews : MMBR · 2025Review
- Screening of Microorganisms Isolated from Stingless Bees' Larval Food in the Biocontrol ofJournal of nematology · 2025Article
- Effect of novel antimicrobial blue light-emitting optical fiber on vancomycin-resistantJournal of bone and joint infection · 2025Article
- Non-Clinical microbiology reviews · 2024Review
- Incidence of group B streptococcus early-onset sepsis in term neonates with second-line prophylaxis maternal intrapartum antibiotics: a multicenter retrospective study.American journal of obstetrics and gynecology · 2024Article
- YajC, a predicted membrane protein, promotesFEMS microbes · 2024Article
- A Photothermally Enhanced Vancomycin-Coated Liquid Metal Antimicrobial Agent with Targeting Capability.Bioengineering (Basel, Switzerland) · 2023Article
- Characterization of vancomycin-resistanceJAC-antimicrobial resistance · 2023Article
- Efficacy of Ursolic Acid-Enriched Water-Soluble and Not Cytotoxic Nanoparticles against Enterococci.Pharmaceutics · 2021Article
- Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.Infection & chemotherapy · 2021Article
- Increasing Trend of Vancomycin-resistant Enterococci Bacteremia in a Tertiary Care Hospital of South India: A Three-year Prospective Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Article
- Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients withAntibiotics (Basel, Switzerland) · 2021Article
- Evaluation of commercial veterinary probiotics containing enterococci for transferrable vancomycin resistance genes.BMC research notes · 2020Article
- VRE in cirrhotic patients.BMC infectious diseases · 2019Article
- Vancomycin-resistant enterococci & healthcare-associated risk factors in paediatric intensive care unit.The Indian journal of medical research · 2019Article
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin and ampicillin resistance in clinical Enterococcus faecium strains has developed in the past decade. Failure to adhere to strict infection control to prevent the spread of these pathogens has been well established. New data implicate the use of specific classes of antimicrobial agents in the spread of vancomycin-resistant enterococci (VRE). Extended-spectrum cephalosporins and drugs with potent activity against anaerobic bacteria may promote infection and colonization with VRE and may exert different effects on the initial establishment and persistence of high-density colonization. Control of VRE will require better understanding of the mechanisms by which different classes of drugs promote gastrointestinal colonization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.